{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T08:13:14Z","timestamp":1794298394893,"version":"4.9.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"43","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ZOLL CMS GmbH"},{"DOI":"10.13039\/100015345","name":"ZOLL Medical France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Patients with newly diagnosed non-ischaemic cardiomyopathy (NICM) or myocardial infarction\/coronary artery disease (MI\/CAD) face an increased risk of sudden cardiac death (SCD) during the early phase of guideline-recommended medical therapy initiation and up-titration. Aim is to evaluate the risk in this population by assessing sudden cardiac arrest (SCA) due to ventricular tachycardia\/ventricular fibrillation (VT\/VF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients in Germany who received a wearable cardioverter-defibrillator (WCD) between December 2021 and May 2023 were enrolled in the observational multicentre SCD-PROTECT study (NCT06883383). The primary outcome was the incidence of SCA due to sustained VT\/VF, measured by appropriate WCD-delivered treatments, and reported as events per 100 patient-years with 95% confidence intervals (CI). Secondary outcomes included inappropriate WCD treatments, all-cause mortality, adverse events, adherence to WCD use, and heart failure medication patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this cohort of 19 598 patients, the mean age (\u00b1standard deviation) was 58.6 \u00b1 13.7 years for those with NICM and 64.2 \u00b1 10.6 years for patients with MI\/CAD. Female patients accounted for 23.8% of the NICM and 16.3% of the MI\/CAD group. Left ventricular ejection fraction (LVEF) at study start was 26.9 \u00b1 10.3% for NICM and 28.4 \u00b1 8.0% for MI\/CAD patients. The incidence rate of first appropriate treatment by WCD in NICM patients and MI\/CAD patients was 6.10 (95% CI 5.31\u20137.00) and 8.64 (95% CI 7.41\u201310.05) events per 100 patient-years, respectively. Overall incidence density for all appropriate treatments was 8.53 (95% CI 7.36\u20139.88) and 14.98 (95% CI 12.69\u201317.65) per 100 patient-years in the respective groups. Improvement in LVEF to &amp;gt;35% was observed in 53.5% of NICM patients and 51.7% of MI\/CAD patients over a mean of 65.9 \u00b1 43.8 days. 36.2% of patients were implanted with a cardioverter-defibrillator at the end of WCD use. Total mortality was 0.8%. Inappropriate shocks occurred in 0.5% of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The SCD-PROTECT study highlights a substantial risk of SCA due to VT\/VF during the early phase of guideline-recommended medical therapy optimization in patients with newly diagnosed reduced LVEF, regardless of ischaemic or non-ischaemic origin. The WCD provided SCD protection, the LVEF could improve to &amp;gt;35% in the majority of these patients and can therefore serve as risk stratification across both aetiologies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaf668","type":"journal-article","created":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T11:23:10Z","timestamp":1755429790000},"page":"4597-4606","source":"Crossref","is-referenced-by-count":32,"title":["Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study"],"prefix":"10.1093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2996-6338","authenticated-orcid":false,"given":"David","family":"Duncker","sequence":"first","affiliation":[{"name":"Hannover Heart Rhythm Center, Department of Cardiology and Angiology, Hannover Medical School , Carl-Neuberg-Str. 1, 30625 Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7227-3428","authenticated-orcid":false,"given":"Eloi","family":"Marijon","sequence":"additional","affiliation":[{"name":"Division of Cardiology, European Georges Pompidou Hospital , Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, PARCC, INSERM U970 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6691-8568","authenticated-orcid":false,"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6311-4983","authenticated-orcid":false,"given":"Olivier","family":"Piot","sequence":"additional","affiliation":[{"name":"Department of Cardiology 2, Centre Cardiologique du Nord , Saint-Denis ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8671-7007","authenticated-orcid":false,"given":"Marat","family":"Fudim","sequence":"additional","affiliation":[{"name":"Cardiology, Duke University , Durham, NC ,","place":["USA"]},{"name":"Duke Clinical Research Institute , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6425-7671","authenticated-orcid":false,"given":"Uwe","family":"Siebert","sequence":"additional","affiliation":[{"name":"UMIT TIROL\u2014University for Health Sciences and Technology, Department of Public Health, Health Services Research and Health Technology Assessment , Hall in Tirol ,","place":["Austria"]},{"name":"Center for Health Decision Science, Departments of Epidemiology and Health Policy & Management, Harvard T.H. Chan School of Public Health , Boston, MA ,","place":["USA"]},{"name":"Program on Cardiovascular Research, Institute for Technology Assessment and Department of Radiology, Massachusetts General Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7611-378X","authenticated-orcid":false,"given":"Norbert","family":"Frey","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology, Pneumology, University Hospital Heidelberg , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9915-4429","authenticated-orcid":false,"given":"Lars Siegfried","family":"Maier","sequence":"additional","affiliation":[{"name":"Internal Medicine II, University Hospital Regensburg ,","place":["Regensburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9341-117X","authenticated-orcid":false,"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[{"name":"Hannover Heart Rhythm Center, Department of Cardiology and Angiology, Hannover Medical School , Carl-Neuberg-Str. 1, 30625 Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"2025111318570135500_ehaf668-B1","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0140-6736(23)00875-9","article-title":"The Lancet Commission to reduce the global burden of sudden cardiac death: a call for multidisciplinary action","volume":"402","author":"Marijon","year":"2023","journal-title":"Lancet"},{"key":"2025111318570135500_ehaf668-B2","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1093\/europace\/euu153","article-title":"Incidence of sudden cardiac death in Germany: results from an emergency medical service registry in Lower Saxony","volume":"16","author":"Martens","year":"2014","journal-title":"Europace"},{"key":"2025111318570135500_ehaf668-B3","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1056\/NEJMoa043938","article-title":"Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both","volume":"352","author":"Solomon","year":"2005","journal-title":"N Engl J Med"},{"key":"2025111318570135500_ehaf668-B4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1001\/jamacardio.2018.1049","article-title":"Sudden death in patients with coronary heart disease without severe systolic dysfunction","volume":"3","author":"Chatterjee","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2025111318570135500_ehaf668-B5","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2025111318570135500_ehaf668-B6","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"key":"2025111318570135500_ehaf668-B7","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2025111318570135500_ehaf668-B8","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s11897-018-0415-7","article-title":"Role of the wearable defibrillator in newly diagnosed heart failure","volume":"15","author":"Duncker","year":"2018","journal-title":"Curr Heart Fail Rep"},{"key":"2025111318570135500_ehaf668-B9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/europace\/euw180","article-title":"The wearable cardioverter-defibrillator: current technology and evolving indications","volume":"19","author":"Reek","year":"2017","journal-title":"Europace"},{"key":"2025111318570135500_ehaf668-B10","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator implantation in patients with nonischemic systolic heart failure","volume":"375","author":"K\u00f8ber","year":"2016","journal-title":"N Engl J Med"},{"key":"2025111318570135500_ehaf668-B11","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1056\/NEJMoa1800781","article-title":"Wearable cardioverter-defibrillator after myocardial infarction","volume":"379","author":"Olgin","year":"2018","journal-title":"N Engl J Med"},{"key":"2025111318570135500_ehaf668-B12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.019124"},{"key":"2025111318570135500_ehaf668-B13","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.19102\/icrm.2018.090506","article-title":"Wearable cardioverter-defibrillators for the prevention of sudden cardiac death: a meta-analysis","volume":"9","author":"Nguyen","year":"2018","journal-title":"J Innov Card Rhythm Manag"},{"key":"2025111318570135500_ehaf668-B14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/europace\/euaa268","article-title":"Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study","volume":"23","author":"Garcia","year":"2021","journal-title":"Europace"},{"key":"2025111318570135500_ehaf668-B15","doi-asserted-by":"publisher","DOI":"10.1161\/circ.150.suppl_1.4142890","article-title":"Risk of life-threatening ventricular arrhythmias in newly diagnosed non-ischemic heart disease\u2014a meta-analysis. AHA24. Chicago. USA","volume":"150","author":"Marijon","year":"2024","journal-title":"Circulation"},{"key":"2025111318570135500_ehaf668-B16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609758","article-title":"Declining risk of sudden death in heart failure","volume":"377","author":"Shen","year":"2017","journal-title":"N Engl J Med"},{"key":"2025111318570135500_ehaf668-B17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter\u2013defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N Engl J Med"},{"key":"2025111318570135500_ehaf668-B18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10840-024-01873-0","article-title":"Incidence and risk factors for first and recurrent ICD shock therapy in patients with an implantable cardioverter defibrillator","volume":"68","author":"Frodi","year":"2025","journal-title":"J Interv Card Electrophysiol"},{"key":"2025111318570135500_ehaf668-B19","doi-asserted-by":"publisher","first-page":"5142","DOI":"10.1002\/ehf2.13586","article-title":"Extended follow-up after wearable cardioverter-defibrillator period: the PROLONG-II study","volume":"8","author":"Mueller-Leisse","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2025111318570135500_ehaf668-B20","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/ejcts\/ezac086","article-title":"Wearable cardioverter defibrillator multicentre experience in a large cardiac surgery cohort at transient risk of sudden cardiac death","volume":"61","author":"Kuehn","year":"2022","journal-title":"Eur J Cardiothorac Surg"},{"key":"2025111318570135500_ehaf668-B21","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"2025111318570135500_ehaf668-B22","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1093\/eurheartj\/ehae334","article-title":"Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study","volume":"45","author":"Veltmann","year":"2024","journal-title":"Eur Heart J"},{"key":"2025111318570135500_ehaf668-B23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12872-018-0790-8","article-title":"Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting","volume":"18","author":"R\u00f6ger","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"2025111318570135500_ehaf668-B24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00392-020-01657-2","article-title":"Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry","volume":"110","author":"Veltmann","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"2025111318570135500_ehaf668-B25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s00059-019-04854-6","article-title":"Avoiding implantation of a cardioverter-defibrillator by bridging with wearable defibrillator vest","volume":"46","author":"Klein","year":"2021","journal-title":"Herz"},{"key":"2025111318570135500_ehaf668-B26","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3390\/s22052037","article-title":"Delayed improvement of left ventricular function in newly diagnosed heart failure depends on etiology-a PROLONG-II substudy","volume":"22","author":"Mueller-Leisse","year":"2022","journal-title":"Sensors (Basel)"},{"key":"2025111318570135500_ehaf668-B27","doi-asserted-by":"publisher","first-page":"4616","DOI":"10.1093\/eurheartj\/ehae326","article-title":"Sudden cardiac death after myocardial infarction: individual participant data from pooled cohorts","volume":"45","author":"Peek","year":"2024","journal-title":"Eur Heart J"},{"key":"2025111318570135500_ehaf668-B28","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s00399-024-01041-x","article-title":"(LV)EF is a poor predictor of sudden cardiac death: pro\/contra","volume":"35","author":"Butter","year":"2024","journal-title":"Herzschrittmacherther Elektrophysiol"},{"key":"2025111318570135500_ehaf668-B29","doi-asserted-by":"publisher","first-page":"e004512","DOI":"10.1161\/JAHA.116.004512","article-title":"Avoiding untimely implantable cardioverter\/defibrillator implantation by intensified heart failure therapy optimization supported by the wearable cardioverter\/defibrillator-the PROLONG study","volume":"6","author":"Duncker","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2025111318570135500_ehaf668-B30","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1093\/eurheartj\/ehab903","article-title":"Fighting against sudden cardiac death: need for a paradigm shift-adding near-term prevention and pre-emptive action to long-term prevention","volume":"43","author":"Marijon","year":"2022","journal-title":"Eur Heart J"},{"key":"2025111318570135500_ehaf668-B31","doi-asserted-by":"publisher","first-page":"euad062","DOI":"10.1093\/europace\/euad062","article-title":"Dynamic changes in nocturnal heart rate predict short-term cardiovascular events in patients using the wearable cardioverter-defibrillator: from the WEARIT-France cohort study","volume":"25","author":"Garcia","year":"2023","journal-title":"Europace"},{"key":"2025111318570135500_ehaf668-B32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ijcard.2022.04.003","article-title":"The value of wearable cardioverter defibrillator in adult patients with recent myocardial infarction: economic and clinical implications from a health technology assessment perspective","volume":"356","author":"Botto","year":"2022","journal-title":"Int J Cardiol"},{"key":"2025111318570135500_ehaf668-B33","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s41669-024-00553-z","article-title":"Cost-utility analysis of LifeVest(R) in post-myocardial infarction patients at risk of sudden cardiac death in England","volume":"9","author":"Kontogiannis","year":"2025","journal-title":"Pharmacoecon Open"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/43\/4597\/64160687\/ehaf668.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/43\/4597\/64160687\/ehaf668.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T23:57:06Z","timestamp":1763078226000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/46\/43\/4597\/8243891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":33,"journal-issue":{"issue":"43","published-online":{"date-parts":[[2025,8,29]]},"published-print":{"date-parts":[[2025,11,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf668","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,14]]},"published":{"date-parts":[[2025,8,29]]}}}